Gilead Sciences Inc. (NASDAQ:GILD) delivered its strongest commercial momentum in several years during fiscal Q2 2026, with growth extending across HIV, oncology, and liver disease portfolios. Total revenue increased 10% year over year to approximately $7.8 billion, while product sales rose 8% to $7.6 billion. Yet the income statement tells a considerably less flattering story: Gilead reported a substantial quarterly loss after recording more than $11 billion in acquired research and development expenses, leaving investors to weigh strengthening commercial performance against an expensive bet on future growth.

Market Context

The results arrive amid heightened scrutiny of biotech dealmaking as the industry seeks to replenish pipelines following years of patent cliffs. Gilead's acquisition spree—targeting Arcellx, Tubulis, and Ouro Medicines—reflects a broader trend of large-cap pharmaceutical companies turning to bolt-on deals to offset declining revenues from legacy drugs. The company's HIV franchise remains the gold standard in its class, but competitors are advancing long-acting injectables that could pressure market share over the coming years.

Analysis

Gilead's underlying business performed robustly during the quarter. Product sales excluding Veklury—the COVID-19 treatment whose revenue has declined—increased 10% to $7.6 billion, demonstrating that growth was driven by the company's core portfolio rather than pandemic-related tailwinds. HIV remained the principal revenue contributor at $5.7 billion, up 12%, with Biktarvy posting a 7% increase to $3.8 billion and Descovy climbing 48% to $967 million. The launch of Yeztugo, Gilead's twice-yearly injectable HIV-prevention medicine, generated $232 million as adoption continued to build.

The liver disease segment provided meaningful acceleration, with sales rising 10% to $877 million on higher demand for Livdelzi and treatments for chronic hepatitis B and hepatitis delta. Livdelzi alone produced $167 million in revenue—more than doubling year over year—a regulatory milestone that expands Gilead's footprint beyond HIV into adjacent therapeutic areas.

Oncology remains a smaller piece of the business but is demonstrating consistent growth trajectory. Trodelvy sales increased 26% to $457 million, driven by higher demand for the breast-cancer treatment. While oncology revenue still represents a fraction of total sales, the franchise's expansion provides evidence that Gilead is building another commercially significant therapeutic area beyond its core HIV business.

The profitability picture, however, presents a stark contrast. The company reported a GAAP loss of $8.45 per share and a non-GAAP loss of $6.75 per share, compared with profits of $1.56 and $2.01 per share, respectively, in the prior-year period. These losses primarily reflected an $9.08-per-share impact from acquired in-process research and development expenses and related taxes associated with the acquisitions of Arcellx, Tubulis, and Ouro Medicines. The $11.2 billion in acquired IPR&D expenses represents a significant capital deployment that will require successful commercialization of pipeline assets to justify.

Management responded by raising the lower end of its 2026 product sales guidance to $30.1–$30.4 billion from the prior range of $30.0–$30.4 billion, while also increasing its forecast excluding Veklury to $29.8–$30.1 billion compared with previous guidance of $29.4–$29.8 billion.

Key Numbers

- Total Q2 revenue: approximately $7.8 billion (+10% year over year)

- Product sales: $7.6 billion (+8%)

- GAAP loss per share: $8.45 (versus $1.56 profit in prior-year period)

- Non-GAAP loss per share: $6.75 (versus $2.01 profit in prior-year period)

- Acquired IPR&D expenses: $11.2 billion ($9.08-per-share impact on EPS)

- HIV sales: $5.7 billion (+12%)

- Biktarvy revenue: $3.8 billion (+7%)

- Descovy sales: $967 million (+48%)

- Yeztugo launch revenue: $232 million

- Liver-disease sales: $877 million (+10%)

- Livdelzi revenue: $167 million (more than doubled year over year)

- Trodelvy sales: $457 million (+26%)

What to Watch

Investors should monitor whether Gilead can successfully integrate its recent acquisitions and advance the acquired pipeline through clinical milestones. The company's raised 2026 guidance suggests management expects underlying momentum to continue, but the substantial R&D write-downs raise questions about capital allocation discipline. Key catalysts include Livdelzi uptake trajectory, Trodelvy's expansion into additional indications, and any updates on the development timelines for assets from Arcellx, Tubulis, and Ouro Medicines. The upcoming FDA review cycle and potential label expansions for existing drugs will be critical in determining whether Gilead can translate acquisition spending into sustainable long-term revenue growth.

The company's ability to maintain HIV franchise pricing power while competing against emerging long-acting injectable therapies from competitors will also merit close attention. Any weakness in the HIV base business could undermine the bull case for the company's growth strategy, regardless of how successful the oncology and liver disease franchises become.